Stock in Focus: Flexion Therapeutics, Inc. (FLXN)

Company Profile:

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Recent News:

On Feb. 07, 2020, the company announced equity inducement grants to 13 new employees consisting of an aggregate of 40,500 stock options and 6,850 restricted stock units.

The company reported unaudited revenue for the fourth quarter of 2019 is estimated to be $23.7 million. Total revenue for the full-year 2019 is estimated to be $73 million. Flexion anticipates 2020 ZILRETTA® product revenue to be in the range of $120 million to $135 million.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

FLXN’s strengths can be seen in its better growth, strong profitability and better efficiency compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, the MACD is trying to cross back up and the RSI stands at 61.18 with positive bias. We rate Flexion Therapeutics, Inc. (FLXN) a STRONG BUY.